ProfileGDS5678 / 1447561_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 24% 24% 24% 23% 24% 24% 24% 24% 24% 24% 24% 24% 24% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5970424
GSM967853U87-EV human glioblastoma xenograft - Control 22.5593824
GSM967854U87-EV human glioblastoma xenograft - Control 32.5614724
GSM967855U87-EV human glioblastoma xenograft - Control 42.4992424
GSM967856U87-EV human glioblastoma xenograft - Control 52.5020823
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6257724
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5911124
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5358124
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5321924
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5466224
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.544324
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5253824
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5529324
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5502324